Ginkgo Bioworks (DNA) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Geron (GERN) has outperformed Ginkgo Bioworks (DNA) over the past year, losing 7.0% versus a loss of 22.6%. Over five years, GERN leads with a -14.9% price change compared with -97.6% for DNA. Geron is the larger company by market cap ($783.8 million vs $763.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | GERN |
|---|---|---|
| Share price | $11.34 | $1.22 |
| Market cap | $763.64M | $783.82M |
| 1-day change | -1.13% | +1.67% |
| YTD return | +38.03% | -9.09% |
| 1-year return | -22.60% | -6.98% |
| 5-year return | -97.59% | -14.89% |
| Forward P/E | — | 30.50 |
| EPS (TTM) | $-5.06 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $2.01 |
| 52-week low | $5.37 | $1.04 |
| Distance from 52-week high | -37.76% | -39.30% |
| Analyst consensus | none | none |
| Avg. price target upside | -38.27% | +248.36% |
| Average volume | 1.77M | 10.09M |
| Shares outstanding | 55.38M | 642.47M |
| Employees | 485 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GERN has outperformed DNA by 15.6 percentage points over the past year.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
DNA vs GERN FAQ
Which is bigger, Ginkgo Bioworks or Geron?
Geron (GERN) is larger, with a market capitalization of $783.82M compared with $763.64M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, DNA or GERN?
GERN returned -6.98% over the past 12 months, compared with -22.60% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and Geron in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Ginkgo Bioworks and Biotechnology: Pharmaceutical Preparations for Geron.